Systematic-Review-Drug-Efficiency-Dissertation-Sample-Work-Tutors-India
Idiopathic Pulmonary Fibrosis (IPF) as the name suggests is a progressive disorder with no known aetiology. It is characterised by the thickening of the alveoli due to scarring resulting in cough. It is known to primarily occur in older adults over 60 years of age. The findings of IPF have a known association of Usual Interstitial Pneumonia (UIP) (Raghu et al., 2011; Kawano-Dourado & Kairalla, 2013; Wells, 2013). It has been deemed that the prognosis is generally poor when UIP has been confirmed (King et al., 2001b). The median survival rate of IPF is 50%, typically around two years after diagnosis (Raghu et al., 2011; King et al., 2001b).
Idiopathic Pulmonary Fibrosis (IPF) as the name suggests is a progressive disorder with no known aetiology. It is characterised by the thickening of the alveoli due to scarring resulting in cough. It is known to primarily occur in older adults over 60 years of age. The findings of IPF have a known association of Usual Interstitial Pneumonia (UIP) (Raghu et al., 2011; Kawano-Dourado & Kairalla, 2013; Wells, 2013). It has been deemed that the prognosis is generally poor when UIP has been confirmed (King et al., 2001b). The median survival rate of IPF is 50%, typically around two years after diagnosis (Raghu et al., 2011; King et al., 2001b).
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary<br />
fibrosis and BOOP. The European respiratory journal. 12 (5). pp. 1010–9.<br />
Nakayama, S., Mukae, H., Sakamoto, N., Kakugawa, T., Yoshioka, S., Soda, H., Oku, H.,<br />
Urata, Y., Kondo, T., Kubota, H., Nagata, K. & Kohno, S. (2008). Pirfenidone inhibits<br />
the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life sciences.<br />
[Online]. 82 (3–4). pp. 210–7. Available from:<br />
http://www.ncbi.nlm.nih.gov/pubmed/18093617.<br />
Nalysnyk, L., Cid-Ruzafa, J., Rotella, P. & Esser, D. (2012). Incidence and prevalence of<br />
idiopathic pulmonary fibrosis: review of the literature. European Respiratory <strong>Review</strong>.<br />
[Online]. 21 (126). pp. 355–361. Available from:<br />
http://err.ersjournals.com/cgi/doi/10.1183/09059180.00002512.<br />
Nathan, S.D., Basavaraj, A., Reichner, C., Shlobin, O.A., Ahmad, S., Kiernan, J., Burton, N.<br />
& Barnett, S.D. (2010). Prevalence and impact of coronary artery disease in idiopathic<br />
pulmonary fibrosis. Respiratory medicine. 104 (7). pp. 1035–41.<br />
Nathan, S.D., Noble, P.W. & Tuder, R.M. (2007). Idiopathic pulmonary fibrosis and<br />
pulmonary hypertension: connecting the dots. American journal of respiratory and<br />
critical care medicine. 175 (9). pp. 875–80.<br />
Nathan, S.D., Shlobin, O.A., Ahmad, S., Koch, J., Barnett, S.D., Ad, N., Burton, N. & Leslie,<br />
K. (2008a). Serial development of pulmonary hypertension in patients with idiopathic<br />
pulmonary fibrosis. Respiration; international review of thoracic diseases. 76 (3). pp.<br />
288–94.<br />
Nathan, S.D., Shlobin, O.A., Barnett, S.D., Saggar, R., Belperio, J.A., Ross, D.J., Ahmad, S.,<br />
Saggar, R., Libre, E., Lynch, J.P. & Zisman, D.A. (2008b). Right ventricular systolic<br />
pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic<br />
pulmonary fibrosis. Respiratory medicine. [Online]. 102 (9). pp. 1305–10. Available<br />
from: http://www.ncbi.nlm.nih.gov/pubmed/18619825.<br />
National Institutes of Health (2011). What Is Idiopathic Pulmonary Fibrosis? [Online]. 2011.<br />
NHLBI. Available from: https://www.nhlbi.nih.gov/health/health-<br />
© 2017-2018 All Rights Reserved, No part of this document should be modified/used without prior consent<br />
<strong>Tutors</strong> <strong>India</strong> - Your trusted mentor since 2001<br />
www.tutorindia.com I UK # +44-1143520021, info@tutorsindia.com<br />
Page 148 of 172
Change language